Eli Lilly and Company clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05
What changed in the last 30 days
44 trials changed in the last 30 days: 0 stopped, 17 with notable changes, 27 with minor changes only.
- Notable: Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma Sponsor changed: Akouos, Inc. to Eli Lilly and Company
- Notable: Follow-up Study of AAVAnc80-antiVEGF Gene Therapy Sponsor changed: Akouos, Inc. to Eli Lilly and Company
- Notable: Follow-up Study of AAVAnc80-hOTOF Gene Therapy Sponsor changed: Akouos, Inc. to Eli Lilly and Company
- Notable: AMPLIFY-2 · EloraTZP · Obesity or Overweight and Type 2 Diabetes Recruitment opened
- Minor: RESTRAIN-SUI · Orforglipron · Stress Urinary Incontinence Who Have Obesity or Overweight Trial sites reduced: 136 → 120 locations
- Minor: ENLIGHTEN-4 · Eloralintide (LY3841136) · Osteoarthritis Knee Pain and Obesity or Overweight Trial sites reduced: 152 → 147 locations
- Minor: SUNRAY-01 · First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy · Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer Trial sites reduced: 418 → 415 locations
- Minor: Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments · Advanced Breast Cancer With a Genetic Change (PIK3CA) Trial sites expanded: 361 → 364 locations
- Minor: FRAmework-01 · Three-Part Phase 3 Study of Sofetabart Mipitecan · Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer Trial sites reduced: 267 → 264 locations
- Minor: RENEW-Op-1 · Brenipatide · Opioid Use Disorder Trial sites expanded: 59 → 68 locations
- Notable: Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US · Early Symptomatic Alzheimer's Disease Primary and study completion moved earlier from Feb 2033 to May 2031
- Minor: LY3867070 in Healthy Participants Trial completed
- Notable: LY3954068 · Early Symptomatic Alzheimer's Disease Primary and study completion pushed from Feb 2027 to Jul 2028
- Minor: Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT) Trial sites expanded: 59 → 62 locations
- Minor: FiREBOLT · LY4337713 · FAP-Positive Solid Tumors Enrollment increased: 241 → 340 participants
- Notable: LY4405094 in Healthy Participants and · Alzheimer's Disease Recruitment opened
- Minor: MOONRAY-01 · LY3962673 · KRAS G12D-Mutant Solid Tumors Enrollment closed, study ongoing
- Minor: CAMPFIRE · Abemaciclib LY2835219 in Participants With Ewing's Sarcoma Study completion pushed from Dec 2026 to Dec 2027
- Notable: ACHIEVE-PEDS · Orforglipron (LY3502970) Compared With Dulaglutide · Type 2 Diabetes Recruitment opened
- Notable: Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment · Moderate-to-Severe Atopic Dermatitis Results posted: Oct 16, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-04 | NCT07914738 A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a) | Phase 1 | Not Yet Recruiting |
| 2026-11-04 | NCT07915245 A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy | Phase 1 | Not Yet Recruiting |
| 2026-10-28 | NCT07900633 A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2… | Phase 3 | Not Yet Recruiting |
| 2026-10-22 | NCT07890376 A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With… | Phase 2 | Not Yet Recruiting |
| 2026-10-20 | NCT07881887 A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2… | Phase 1 | Not Yet Recruiting |
| 2026-10-20 | NCT07883590 A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral… | Phase 1 | Not Yet Recruiting |
| 2026-10-19 | NCT07881432 A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Phase 3 | Not Yet Recruiting |
| 2026-10-19 | NCT07881458 A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Recruiting |
| 2026-10-09 | NCT07867327 A Study of LY4515100 in Healthy Male Participants | Phase 1 | Not Yet Recruiting |
| 2026-10-09 | NCT07867340 A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including… | Phase 1 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 72 | |
| Phase 1/2 | 6 | |
| Phase 2 | 43 | |
| Phase 2/3 | 1 | |
| Phase 3 | 94 | |
| Phase 4 | 11 |
Not charted: 8 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 58
Obesity (56) · Diabetes (28) · Breast Cancer (24) · Type 2 Diabetes (21) · Alzheimer's Disease (19) · Dementia (19) · Lung Cancer (19) · Non-Small Cell Lung Cancer (NSCLC) (19) · Colorectal Cancer (10) · Head & Neck Cancer (8)
Get alerts when Eli Lilly and Company's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.